There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lisata Therapeutics (LSTA – Research Report) and Bolt Biotherapeutics (BOLT – Research Report) with bullish sentiments. Lisata Therapeutics (LSTA) In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lisata Therapeutics, with a price target of $15.00. The company's shares closed last Thursday at $3.70, close to its 52-week low of $3.50. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lisata-therapeutics-lsta-and-bolt-biotherapeutics-bolt?utm_source=advfn.com&utm_medium=referral
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Lisata Therapeutics Charts.
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Lisata Therapeutics Charts.